美国医院分离的肺炎链球菌对头孢洛林及对照药物的活性：AWARE 监测项目（2010 至 2016 年）七年的结果。
Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
University of Iowa, Iowa City, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01555-17. Print 2018 Feb.
Abstract
We evaluated trends in antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against (>99.9%) with no marked variations.
摘要
我们评估了 2010 年至 2016 年期间美国医院的抗菌药物敏感性趋势。对来自 47 个医疗中心的 8768 株临床分离株进行肉汤微量稀释法药敏试验。2010 年，耐多药（MDR）和广泛耐药（XDR）的发生率分别为 25.7%和 12.4%，到 2016 年分别下降至 17.7%和 3.6%。大多数比较抗菌药物的敏感性增加，而头孢洛林、左氧氟沙星、利奈唑胺和替加环素的敏感性保持稳定。头孢洛林对 （>99.9%）保持强效活性，无明显变化。
相似文献
1
Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).美国医院分离的肺炎链球菌对头孢洛林及对照药物的活性：AWARE 监测项目（2010 至 2016 年）七年的结果。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01555-17. Print 2018 Feb.
2
Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate.头孢洛林对来自美国医疗中心的耐多药肺炎链球菌的活性（2014年）以及一株对头孢洛林不敏感菌株的分子特征分析
Microb Drug Resist. 2017 Jul;23(5):571-579. doi: 10.1089/mdr.2016.0258. Epub 2016 Dec 5.
3
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).头孢洛林对耐多药金黄色葡萄球菌和肺炎链球菌的体外活性：对已发表研究和 AWARE 监测计划（2008-2010 年）的回顾。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563.
4
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.AWARE 头孢洛林监测计划（2008-2010 年）：美国肺炎链球菌、流感嗜血杆菌和卡他莫拉菌耐药模式的趋势。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93. doi: 10.1093/cid/cis561.
5
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.针对左氧氟沙星不敏感的肺炎链球菌所致感染，在广谱β-内酰胺类药物中的治疗选择。
Diagn Microbiol Infect Dis. 2005 Jun;52(2):129-33. doi: 10.1016/j.diagmicrobio.2004.12.009.
6
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).美国肺炎链球菌对抗菌药物敏感性趋势的最新情况：来自 SENTRY 抗菌药物监测计划（1998-2011 年）的头孢洛林活性报告。
Diagn Microbiol Infect Dis. 2013 Jan;75(1):107-9. doi: 10.1016/j.diagmicrobio.2012.08.024. Epub 2012 Sep 23.
7
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.头孢洛林对美国医院儿科患者中引起社区获得性呼吸道感染及皮肤和皮肤结构感染的细菌分离株的活性测试：2012 - 2014年
Pediatr Infect Dis J. 2017 May;36(5):486-491. doi: 10.1097/INF.0000000000001477.
8
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.头孢洛林对耐头孢菌素肺炎链球菌分离株抗菌活性的体外评价
Antimicrob Agents Chemother. 2009 Feb;53(2):552-6. doi: 10.1128/AAC.01324-08. Epub 2008 Nov 17.
9
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.在美国医疗中心对肺炎链球菌耐药亚群进行测试时头孢洛林的抗菌活性。
Antimicrob Agents Chemother. 2014;58(4):2468-71. doi: 10.1128/AAC.02557-13. Epub 2014 Feb 10.
10
Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.头孢洛林对美国医疗中心常见分离出的细菌病原体的活性：AWARE监测项目五年的结果。
Antimicrob Agents Chemother. 2015 Apr;59(4):2458-61. doi: 10.1128/AAC.04614-14. Epub 2015 Feb 2.
引用本文的文献
1
Antibiotic Treatment of Pulmonary Infections: An Umbrella Review and Evidence Map.肺部感染的抗生素治疗：一项伞状综述与证据图谱
Front Pharmacol. 2021 Oct 19;12:680178. doi: 10.3389/fphar.2021.680178. eCollection 2021.
2
A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant in Ambulatory and Hospitalized Adult Patients in the United States.美国门诊和住院成年患者中耐大环内酯类药物的患病率及地区差异的多中心评估
Open Forum Infect Dis. 2021 Feb 4;8(7):ofab063. doi: 10.1093/ofid/ofab063. eCollection 2021 Jul.
3
Serotype distribution and antimicrobial susceptibility of isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial.一项III期社区获得性细菌性肺炎（CABP）试验中分离株的血清型分布及抗菌药物敏感性
JAC Antimicrob Resist. 2021 May 4;3(2):dlab057. doi: 10.1093/jacamr/dlab057. eCollection 2021 Jun.
4
Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.碳青霉烯类抗生素会导致耐甲氧西林金黄色葡萄球菌（MRSA）感染的囊性纤维化患者对头孢洛林产生间接耐药性。
Commun Biol. 2020 Oct 22;3(1):599. doi: 10.1038/s42003-020-01313-5.
5
Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.2009 年至 2018 年美国眼部微生物的抗生素耐药趋势。
JAMA Ophthalmol. 2020 May 1;138(5):439-450. doi: 10.1001/jamaophthalmol.2020.0155.
6
Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models.口服和静脉注射每日一次氨甲基环素抗生素用于社区获得性细菌性肺炎住院患者的成本节约机会：决策分析模型的结果
Am Health Drug Benefits. 2019 Jun-Jul;12(4):168-176.
7
Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.索利霉素对肺炎链球菌的药代动力学/药效学评价：来自中性粒细胞减少症小鼠肺部感染模型的数据。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.02606-18. Print 2019 Aug.
8
Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.头孢洛林治疗社区获得性肺炎的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
J Clin Med. 2019 Jun 9;8(6):824. doi: 10.3390/jcm8060824.
9
Antimicrobial Susceptibility of from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).来自北美、欧洲、拉丁美洲和亚太地区的抗菌药物敏感性：哨兵抗菌药物监测计划20年（1997 - 2016年）的结果
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S14-S23. doi: 10.1093/ofid/ofy263. eCollection 2019 Mar.
10
Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).眼部病原体的抗生素耐药性：ARMOR监测研究（2009 - 2016年）的当前趋势
Clin Optom (Auckl). 2019 Mar 12;11:15-26. doi: 10.2147/OPTO.S189115. eCollection 2019.
本文引用的文献
1
Genomic Epidemiology of Penicillin-Nonsusceptible Pneumococci with Nonvaccine Serotypes Causing Invasive Disease in the United States.美国非疫苗血清型青霉素不敏感肺炎球菌引起侵袭性疾病的基因组流行病学
J Clin Microbiol. 2017 Apr;55(4):1104-1115. doi: 10.1128/JCM.02453-16. Epub 2017 Jan 18.
2
Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate.头孢洛林对来自美国医疗中心的耐多药肺炎链球菌的活性（2014年）以及一株对头孢洛林不敏感菌株的分子特征分析
Microb Drug Resist. 2017 Jul;23(5):571-579. doi: 10.1089/mdr.2016.0258. Epub 2016 Dec 5.
3
Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.2007 - 2013年加拿大耐多药和广泛耐药肺炎链球菌的特征分析
J Antimicrob Chemother. 2015 Aug;70(8):2199-202. doi: 10.1093/jac/dkv107. Epub 2015 Apr 28.
4
Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.美国引入13价结合疫苗后肺炎球菌血清型及抗菌药物耐药性的变化
Antimicrob Agents Chemother. 2014 Nov;58(11):6484-9. doi: 10.1128/AAC.03344-14. Epub 2014 Aug 18.
5
Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.13价肺炎球菌结合疫苗引入前后收集的美国肺炎链球菌分离株的血清型分布及抗菌药物敏感性
Diagn Microbiol Infect Dis. 2014 Sep;80(1):19-25. doi: 10.1016/j.diagmicrobio.2014.05.020. Epub 2014 May 24.
6
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.2011 - 2012年美国新出现的（35B和6C）及持续存在的（19A）肺炎链球菌血清型中头孢曲松敏感性降低：头孢洛林在β - 内酰胺类药物中体外仍保持活性。
Antimicrob Agents Chemother. 2014 Aug;58(8):4923-7. doi: 10.1128/AAC.02976-14. Epub 2014 May 27.
7
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.在美国医疗中心对肺炎链球菌耐药亚群进行测试时头孢洛林的抗菌活性。
Antimicrob Agents Chemother. 2014;58(4):2468-71. doi: 10.1128/AAC.02557-13. Epub 2014 Feb 10.
8
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.头孢洛林酯：在治疗复杂性皮肤和软组织感染及社区获得性肺炎中的应用评价。
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
9
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).美国肺炎链球菌对抗菌药物敏感性趋势的最新情况：来自 SENTRY 抗菌药物监测计划（1998-2011 年）的头孢洛林活性报告。
Diagn Microbiol Infect Dis. 2013 Jan;75(1):107-9. doi: 10.1016/j.diagmicrobio.2012.08.024. Epub 2012 Sep 23.
10
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).头孢洛林对耐多药金黄色葡萄球菌和肺炎链球菌的体外活性：对已发表研究和 AWARE 监测计划（2008-2010 年）的回顾。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563.
Zotero 插件